NLRP3 and Alzheimer disease: All these observations, together with the decreased insoluble Aβ plaques, suggest that pharmacologically restoring mitophagy improves phagocytosis and reduces NLRP3- mediated inflammation in AD models, therefore improving AD pathogenesis (Fang et al., 2019; Lautrup et al., 2019).